Recurrent Lung Non-Small Cell Carcinoma

Oncology·MeSH: Carcinoma, Non-Small-Cell Lung

9 drugs in development·2 companies·9 clinical trials

Drug Pipeline by Phase

Phase 3(9)

Drug	Company
capmatinib	GH Research PLC (GHRS)
cemiplimab	GH Research PLC (GHRS)
chemotherapy	GH Research PLC (GHRS)
chemotherapy	GH Research PLC (GHRS)
Etoposide	ADMA BIOLOGICS, INC. (ADMA)
osimertinib	GH Research PLC (GHRS)
Pemetrexed Disodium	ADMA BIOLOGICS, INC. (ADMA)
ramucirumab	GH Research PLC (GHRS)
tepotinib	GH Research PLC (GHRS)

Compare drugs

capmatinib vs cemiplimab capmatinib vs chemotherapy capmatinib vs Etoposide

Frequently asked questions

How many drugs are in development for Recurrent Lung Non-Small Cell Carcinoma?

BioSniper tracks 9 drugs in development for Recurrent Lung Non-Small Cell Carcinoma across 2 companies.

How many clinical trials target Recurrent Lung Non-Small Cell Carcinoma?

There are 9 clinical trials targeting Recurrent Lung Non-Small Cell Carcinoma tracked by BioSniper.

Deep-dive into Recurrent Lung Non-Small Cell Carcinoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Recurrent Lung Non-Small Cell Carcinoma — Drugs in Development & Clinical Trials | BioSniper